Skip to main content
. 2021 May 24;11:662392. doi: 10.3389/fonc.2021.662392

Figure 5.

Figure 5

Forest plots of all-grade treatment-related adverse events. (A) The odds ratio of all-grade treatment-related adverse events calculated by the random effect (RE) model in Group A (PD-1/PD-L1 vs Chemotherapy). Subgroup analysis was performed based on tumor types, PD-1/PD-L1 and treatment regimens. (B) The odds ratio of all-grade treatment-related adverse events calculated by the random effect (RE) model in Group B (PD-1/PD-L1 + Chemotherapy vs Chemotherapy). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (C) The odds ratio of all-grade treatment-related adverse events calculated by the random effect (RE) model in Group C (PD-1/PD-L1 vs Placebo). Subgroup analysis was performed based on PD-1/PD-L1 and tumor types. (D) The odds ratio of all-grade treatment-related adverse events calculated by the random effect (RE) model in Group D (PD-1 vs PD-1 + CTLA-4). Subgroup analysis was performed based on tumor types. (E) The odds ratio of all-grade treatment-related adverse events calculated by the random effect (RE) model in Group E (PD-1 + CTLA-4 vs CTLA-4). (F) The odds ratio of all-grade treatment-related adverse events calculated by the random effect (RE) model in Group F (PD-1 vs CTLA-4).